Biosketch Nicolás Herranz

Nicolás Herranz

nherranz@vhio.net

Current position

Senior Researcher of VHIO´s Prostate Cancer Translational Research Group

Academic Qualifications

2011 – PhD in Biomedicine. Universitat Pompeu Fabra, Barcelona, Spain
2007 – MS in Biomedicine. Universitat Pompeu Fabra, Barcelona, Spain
2006 – BSc in Human Biology. Universitat Pompeu Fabra, Barcelona, Spain

Work Experience

2020 – present: Senior Investigator – Miguel Servet I tenure-track. Prostate Cancer Translational Research Group, Vall d’Hebrón Institute of Oncology, Barcelona, Spain.
2019: Senior Postdoctoral Researcher. Prostate Cancer Translational Research Group, Vall d’Hebrón Institute of Oncology, Barcelona, Spain.
2012 – 2018: Postdoctoral Researcher. Cell proliferation Group, MRC London Medical Science, Imperial College, London, UK.
2007-2011: PhD student (FPU fellowship from Spanish Ministry for Education and Science). Tumor progression lab, IMIM institute, Barcelona, Spain.

Awards and Honors

2021: XX Beca Fero
2019: Miguel Servet I Program, tenure-track investigator, Spain.
2019: Marie Curie Individual Fellowship. European Commission (Not accepted)
2019: Postdoctoral Beatriu de Pinós grant (Not accepted)
2015 & 2017: End of Year Special Award for outstanding contribution to the MRC-LMS
2012: Postdoctoral EMBO long-term fellowship

Research Support

As PI

Exploiting therapy-induced senescence to treat advanced Prostate Cancer – Instituto de Salud Carlos III (2021-2024). 125.000€
Therapy-induce senescence in Prostate Cancer – XX Beca Fero (2022-2024). 80.000€

As Co-investigator

Developing synergistic combinations of olaparib with other DNA repair targeting agents and BET inhibition in prostate cancer – Astrazeneca (2021-2024). 398.700€ PI: Joaquín Mateo
Senescence and Cell proliferation (Core funding) – Medical Research Council (2016 – 2021)1.980.000 €. PI: Jesus Gil.
Identification of novel senolytic compounds – Unity Biotechnology (2017 – 2020) 1.010.000 €PI: Jesus Gil.
Compounds killing senescent cells – MRC-Technology (2016 – 2018) – 155.273 € PI: Jesus Gil.
Senescence and Cell proliferation (Core funding) – Medical Research Council (2011 – 2016)1.893.000 €. PI: Jesus Gil
H3K4 deamination by LOXL2 – Instituto de Salud Carlos III (2008-2013) 45.000 € PI: Sandra Peiró.
Chromatin structure regulation by LOXL2 – Instituto de Salud Carlos III (2009-2012) 68.335 €PI: Sandra Peiró.

Patents

2019
Title: Senolytic compounds (US patent)
Inventors: Nicolas Herranz, Ana Guerrero, Jesus Gil
Applicant: Medical Research Council, UK
Patent registration number: 16/616,251
2017
Title: Prodrugs
Inventors: Nicolas Herranz, Ana Guerrero, Jesus Gil
Applicant: Medical Research Council, UK
Patent number: GB1708458.3
2017
Title: Senolytic compounds
Inventors: Nicolas Herranz, Ana Guerrero, Jesus Gil
Applicant: Medical Research Council, UK
Patent number: GB1708456.7

Mentorings

I am currently co-directing Julian Brandariz’s PhD thesis (2021-present) and I have supervised 3 Master Student’s projects.

2013 Suchira Gallage – Role of S6 Kinases in Senescence and Ageing
2011 Ane Itúrbide – Chromatin structure regulation by LOXL2
2010 Alba Millanes – Characterization of Snail binding sites in EMT

Most relevant scientific publications

Herranz N*, Neeb A*, Arce-Gallego S*, Miranda S, Buroni L, Yuan W et al. Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. Eur Urol. 2021 Feb;79(2):200-211. doi: 10.1016/j.eururo.2020.10.029. Epub 2020 Nov 8. PMID: 33176972. *Equally contributed
Guerrero A, Guiho R, Herranz N, Uren A, Withers DJ, Martínez-Barbera JP, Tietze LF, Gil J. Galactose-modified Duocarmycin Prodrugs as Senolytics, Aging Cell. 2020 Apr;19(4):e13133.
Guerrero A, Herranz N, Sun B, Wagner V, Gallage S, Guiho R, Wolter K, Pombo J, Irvine EE, Innes AJ, Birch J, Glegola J, Manshaei S, Heide D, Dharmalingam G, Harbig J, Olona A, Behmoaras J, Dauch D, Uren AG, Zender L, Vernia S, Martínez-Barbera JP, Heikenwalder M, Withers DJ, Gil J. Cardiac glycosides are broad-spectrum senolytics. Nature Metabolism, 2019 Nov;1(11):1074-1088.
Georgilis A, Klotz S, Hanley CJ, Herranz N, Weirich B, Morancho B, Leote AC, D’Artista L, Gallage S, Seehawer M, Carroll T, Dharmalingam G, Wee KB, Mellone M, Pombo J, Heide D, Guccione E, Arribas J, Barbosa-Morais NL, Heikenwalder M, Thomas GJ, Zender L, Gil J. PTBP1-Mediated Alternative Splicing Regulates the Inflammatory Secretome and the Pro-tumorigenic Effects of Senescent Cells. Cancer Cell 2018 Jul; 34(1):85-102.
Herranz N, Gil J. Mechanisms and functions of cellular senescence. J Clin Invest 2018 Apr; 128(4): 1238-1246.
Mellone M, Hanley CJ, Thirdborough S, Mellows T, Garcia E, Woo J, Tod J, Frampton S, Jenei V, Moutasim KA, Kabir TD, Brennan PA, Venturi G, Ford K, Herranz N, Lim KP, Clarke J, Lambert DW, Prime SS, Underwood TJ, Vijayanand P, Eliceiri KW, Woelk C, King EV, Gil J, Ottensmeier CH, Thomas GJ. Induction offibroblast senescence generates a non-fibrogenic myofibroblast phenotype thatdifferentially impacts on cancer prognosis. Aging (Albany NY). 2016 Dec 15.
Herranz N, Dave N, Millanes-Romero A, Pascual-Reguant L, Morey L, Díaz VM, Lórenz-Fonfría V, Gutierrez-Gallego R, Jerónimo C, Iturbide A, Di Croce L, García de Herreros A, Peiró S. Lysyl oxidase-like 2 (LOXL2) oxidizes trimethylated lysine 4 in histone H3. FEBS J. 2016 Dec;283(23):4263-4273
Herranz N, Gil J. Mitochondria and senescence: new actors for an old play. EMBO J. 2016 Apr 1;35(7):701-2.
Herranz N, Gallage S, Gil J. TORn about SASP regulation. Cell Cycle. 2015;14(24):3771-2.
Herranz N, Gallage S, Mellone M, Wuestefeld T, Klotz S, Hanley CJ, Raguz S, Acosta JC, Innes AJ, Banito A, Georgilis A, Montoya A, Wolter K, Dharmalingam G, Faull P, Carroll T, Martínez-Barbera JP, Cutillas P, Reisinger F, Heikenwalder M, Miller RA, Withers D, Zender L, Thomas GJ, Gil J. mTOR regulates MAPKAPK2translation to control the senescence-associated secretory phenotype. Nat Cell 2015 Sep;17(9):1205-17.
Millanes-Romero A, Herranz N, Perrera V, Iturbide A, Loubat-Casanovas J, Gil J, Jenuwein T, García de Herreros A, Peiró S. Regulation of heterochromatin transcription by Snail1/LOXL2 during epithelial-to-mesenchymal transition. Mol Cell. 2013 Dec 12;52(5):746-57.
Herranz N, Pasini D, Díaz VM, Francí C, Gutierrez A, Dave N, Escrivà M, Hernandez-Muñoz I, Di Croce L, Helin K, García de Herreros A, Peiró S. Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription Mol Cell Biol. 2008 Aug;28(15):4772-81.
Escrivà M, Peiró S, Herranz N, Villagrasa P, Dave N, Montserrat-Sentís B, Murray SA, Francí C, Gridley T, Virtanen I, García de Herreros A. Repression of PTEN phosphatase by Snail1 transcriptional factor during gamma radiation-induced Mol Cell Biol. 2008 Mar;28(5):1528-40.
Peiró S, Escrivà M, Puig I, Barberà MJ, Dave N, Herranz N, Larriba MJ, Takkunen M, Francí C, Muñoz A, Virtanen I, Baulida J, García de Herreros A. Snail1 transcriptional repressor binds to its own promoter and controls its Nucleic Acids Res. 2006 Apr 14;34(7):2077-84.

All publications

Joaquin Mateo , Gopinath Ganji , Charlotte Lemech , Howard A. Burris , Sae-Won Han , Karen Swales , Shaun Decordova , Maurice P DeYoung , Deborah A Smith , Shanker Kalyana-Sundaram , Jiuhua Wu , Monica Motwani , Rakesh Kumar , Jerry M Tolson , Sun Young Rha , Hyun Cheol Chung , Joseph Paul Eder , Sunil Sharma, Yung-Jue Bang , Jeffrey R. Infante ,Li Yan, Johann de Bono, Hendrik-Tobias Arkenau. A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2017 Oct 1;23(19):5981-5992.
Seed G, Yuan W, Mateo J, Carreira S, Bertan C, Lambros M, Boysen G, Ferraldeschi R, Miranda S, Figueiredo I, Riisnaes R, Crespo M, Rodrigues DN, Talevich E, Robinson DR, Kunju LP, Wu YM, Lonigro R, Sandhu S, Chinnayan A, de Bono JS. Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification. Clin Cancer Res. 2017 Oct 15;23(20):6070-6077.
Goodall J*, Mateo J*, Yuan W, Mossop H, Porta N, Miranda S, Perez-Lopez R, Dolling D, Robinson DR, Sandhu S, Fowler G, Ebbs B, Flohr P, Seed G, Nava Rodrigues D, Boysen G, Bertan C, Atkin M, Clarke M, Crespo M, Figueiredo I, Riisnaes R, Sumanasuriya S, Rescigno P, Zafeiriou Z, Sharp A, Tunariu N, Bianchini D, Gillman A, Lord CJ, Hall E, Chinnaiyan AM, Carreira S, de Bono JS. Circulating Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. Cancer Discovery. 2017 Apr 27 [Epub ahead of print] DOI: 10.1158/2159-8290.CD-17-0261
Massard C, Mateo J, Loriot Y, Pezaro C, Albiges L, Mehra N, Varga A, Bianchini D, Ryan CJ, Petrylak DP, Attard G, Shen L, Fizazi K, de Bono J. : Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. Annals of Oncology. 2017 Jan 1;28(1):90-95
Pritchard C*, Mateo J*, Walsh M*, de Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin M, Robinson D, Lonigro R, Hussein M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, Aldubayan S, Han C, Beightol M, Morissey C, Nghiem B, Cheng H, Montgomery B, Walsh T, Casadei S, Vijai J, Scher H, Sawyers C, Schultz N, Kantoff P, Solit D, Robson M, Van Allen E, Offit K, de Bono JS, Nelson P. (on behalf of the SU2C-PCF Prostate Cancer Dream Team] Inherited DNA repair gene mutations in men with metastatic prostate cancer. N Engl J Med, 2016; 375(5)443-45.
Mateo J,* Carreira S*, Sandhu S*, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, Brough R, Pemberton H, A’Hern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM, Hall E, de Bono JS. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. 2015. N Engl J Med 373(18):1697-1708.
Robinson D, Van Allen EM, Wu Y-M, Schultz N, Lonigro R, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng F, Tomlins SA, Conney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu, EY, Mostaghel EA, Cheng HH, Mulcahy H, True L, Plymate SR, Dyinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson B, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PA, Garraway LA, Sawyers CL, Chinnaiyan AM. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161(5):1215–28.
Perez-Lopez R, Mateo J, Mossop H, Blackledge MD, Collins DJ, Rata M, Morgan VA, Macdonald A, Sandhu S, Lorente D, Rescigno P, Zafeiriou Z, Bianchini D, Porta N, Hall E, Leach MO, de Bono JS, Koh DM, Tunariu N. Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. Radiology. 2017 Apr;283(1):168-177
Perez-Lopez R, Lorente D, Blackledge MD, Collins DJ, Mateo J, Bianchini D, Omlin A, Zivi A, Leach MO, de Bono JS, Koh DM, Tunariu N. Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer. Radiology 2016; 280(1):151-160.
Ferraldeschi R, Nava D, Riisnaes R, Miranda S, Figueiredo I, Rescigno P, Ravi P, Pezaro C, Omlin A, Lorente D, Zafeiriou Z, Mateo J, Altavilla A, Sideris S, Bianchini D, Girst E, Thway K, Perez-Lopez R, Tunariu N, Parker C, Dearnaley D, Reid A, Attard G, de Bono JS. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. European Urology 2015;67(4):795–802.
Mateo J, Olmos D, Dumez H, Poondru S, Samberg N, Barr S, Van Tornout JM, Jie F, Sandhu S, Tan DS, Moreno V, LoRusso PM, Kaye SB, Schoffski P. A first-in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies. Br J Cancer 2016, 114, 889-896
Mateo J, Moreno V, Gupta A, Kaye SB, Dean E, Middleton MR, Friedlander M, Gourley C, Plummer R, Rustin G, Sessa C, Leunen K, Ledermann J, Swaisland H, Fielding A, Bannister W, Nicum S, Molife LR. An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor Olaparib. Target Oncol. 2016 Jun;11(3):401-15
McDaniel AS, Ferraldeschi R, Krupa R, Landers M, Graf R, Louw J, Jendrisak A, Bales N, Marrinucci D, Zafeiriou Z, Flohr P, Sideris S, Crespo M, Figueiredo I, Mateo J, de Bono JS, Dittamore R, Tomlins SA, Attard G. Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer. BJU Int. 2016 Aug (EPub)
Rescigno P, Lorente D, Bianchini D, Ferraldeschi R, Kolinsky MP, Sideris S, Zafeiriou Z, Sumanasuriya S, Smith AD, Mehra N, Jayaram A, Perez-Lopez R, Mateo J, Parker C, Dearnaley DP, Tunariu N, Reid A, Attard G, de Bono JS. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. European Urology. 2016 Nov;70(5):724-731.
Lorente D, Olmos D, Mateo J, Bianchini D, Seed G, Fleisher M, Danila DC, Flohr P, Crespo M, Figueiredo I, Miranda S, Baeten K, Molina A, Kheoh T, McCormack R, Terstappen LW, Scher HI, de Bono JS. Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer. European Urology. 2016; 70*6)985-992.
Lorente D, Omlin A, Zafeiriou Z, Nava-Rodrigues D, Pérez-López R, Pezaro C, Mehra N, Sheridan E, Figueiredo I, Riisnaes R, Miranda S, Crespo M, Flohr P, Mateo J, Altavilla A, Ferraldeschi R, Bianchini D, Attard G, Tunariu N, de Bono J. Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses. Clin Genitourin Cancer. 2016 Dec;14(6):485-493
Frenel J-S, Carreira S, Goodall J, Roda-Perez D, Perez-Lopez R, Tunariu N, Riisnaes R, Miranda S, Figueiredo I, Nava Rodrigues D, Smith A, Leux C, Garcia-Murillas I, Ferraldeschi R, Lorente D, Mateo J, Ong M, Yap TA, Banerji U, Gasi D, Turner N, Attard G, de Bono JS. Serial Next Generation Sequencing of Circulating Cell Free DNA Evaluating Tumour Clone Response To Molecularly Targeted Drug Administration. Clin Cancer Res 2015; 21(20):4586-96.
Lorente D, Mateo J, Templeton AJ, Zafeiriou Z, Bianchini D, Ferraldeschi R, Bahl A, Shen L, Su Z, Sartor O, de Bono JS. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol. 2015 Apr;26(4):750-5
Ferraldeschi R, Nava Rodrigues D, Riisnaes R, Miranda S, Figueiredo I, Rescigno P, Ravi P, Pezaro C, Omlin A, Lorente D, Zafeiriou Z, Mateo J, Altavilla A, Sideris S, Bianchini D, Grist E, Thway K, Perez Lopez R, Tunariu N, Parker C, Dearnaley D, Reid A, Attard G, de Bono J. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur Urol. 2015 Apr;67(4):795-802
Wilbaux M, Tod M, De Bono J, Lorente D, Mateo J, Freyer G, You B, Hénin E. A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer. CPT Pharmacometrics Syst Pharmacol. 2015 May;4(5):277-85
Mateo J, Berlin J, de Bono JS, Cohen RB, Keedy V, Mugundu G, Zhang L, Abbattista A, Davis C, Gallo Stampino C, Borghaei H. A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors. Cancer Chemother Pharmacol 2014, 74(5):1039-46.
Ong M, Carreira S, Goodall J, Mateo J, Figueiredo I, Rodrigues DN, Perkins G, Seed G, Yap TA, Attard G, de Bono JS. Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail. Br J Cancer 2014;111(5):828-36.
Ravi P, Mateo J, Lorente D, Zafeiriou Z, Altavilla A, Ferraldeschi R, Sideris S, Grist E, Smith A, Wong S, Bianchinni D, Attard G, de Bono JS. External Validation of a Prognostic Model Predicting Overall Survival in Metastatic Castrate-resistant Prostate Cancer Patients Treated with Abiraterone. European Urology 2014;66(1):8–11.
Barber LJ, Sandhu S, Chen L, Campbell J, Kozarewa I, Fenwick K, Assiotis I, Rodrigues DN, Reis Filho JS, Moreno V, Mateo J, Molife LR, De Bono J, Kaye S, Lord CJ, Ashworth A. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol. 2013 Feb;229(3):422-9.
Mateo J, Carreira S, de Bono JS. Acquiring evidence for precision prostate cancer care. Annals Oncology. 2017 Apr 13. (Epub ahead of print)
Mateo J, Sharp A, de Bono JS. Investigating Genomic Aberrations of the Androgen Receptor: Moving Closer to More Precise Prostate Cancer Care? European Urology. 2017 Feb 20.
Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, Olmos D, Pritchard CC, Rubin MA, de Bono JS. DNA Repair in Prostate Cancer: Biology and Clinical Implications. European Urology. 2017 Mar;71(3):417-425.
Lorente D, Mateo J, Perez-Lopez R, de Bono JS, Attard G. Sequencing agents in metastatic prostate cancer. Lancet Oncology 2015 Jun;16(6):e279-92.
Lorente D, Mateo J, Zafeiriou Z, Smith AD, Sandhu S, Ferraldeschi R, de Bono JS. Switching and withdrawing hormonal agents for castration-resistant prostate cancer. Nat Rev Urol. 2015 Jan;12(1):37-47.
Mateo J, Gerlinger M, Rodrigues DN, de Bono JS. The promise of circulating tumor cell analysis in cancer management Genome Biol. 2014 Aug 30;15(8):448.
Mateo J, Ong M, Tan DS, Gonzalez MA, de Bono JS. Appraising iniparib, the PARP inhibitor that never was–what must we learn? Nat Rev Clin Oncol. 2013 Dec;10(12):688-96.